dectrekumab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
dectrekumab

GtoPdb Ligand ID: 8714

Synonyms: QAX-576 | QAX576

Compound class: Antibody

Comment: Dectrekumab is a fully human investigational anti-interleukin 13 (IL-13) monoclonal antibody, with anti-inflammatory potential.
Peptide sequence and secondary structural information are available from dectrekumab's IMGT/mAb-DB record.
Peptide sequences for the heavy and light chains of dectrekumab match those provided in patent US8992916 B2 for clone 01951/G12 [1].

No information available.

No information available.

Summary of Clinical Use
Dectrekumab (QBX258) reached Phase 2 clinical trial as a potential biologic therapy for several immune conditions, including idiopathic pulmonary fibrosis (IPF), asthma, eosinophilic esophagitis [2] (proof of principle study NCT01022970), Crohn's disease, keloids and allergic rhinitis. As of May 2017, there are no active dectrekumab studies.

Summary of Clinical Use

Dectrekumab (QBX258) reached Phase 2 clinical trial as a potential biologic therapy for several immune conditions, including idiopathic pulmonary fibrosis (IPF), asthma, eosinophilic esophagitis [2] (proof of principle study NCT01022970), Crohn's disease, keloids and allergic rhinitis. As of May 2017, there are no active dectrekumab studies.

Mechanism Of Action and Pharmacodynamic Effects
Treatment with dectrekumab therapy has been shown to modulate a set of human genes indicative of a TH₂-driven mechanism of action in eosinophilic esophagitis [2]. Such results suggest that other TH₂-driven diseases may be amenable to the same therapeutic approach.

Mechanism Of Action and Pharmacodynamic Effects

Treatment with dectrekumab therapy has been shown to modulate a set of human genes indicative of a TH₂-driven mechanism of action in eosinophilic esophagitis [2]. Such results suggest that other TH₂-driven diseases may be amenable to the same therapeutic approach.